Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

Radwa Ewaisha, Karen S. Anderson

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinical development of CRISPR therapeutics leverages years of experience with gene therapy successes and failures. Adverse events due to immunogenicity have been a major setback that has impacted the field of gene therapy. As several in vivo CRISPR clinical trials make progress, the challenge of immunogenicity remains a significant roadblock to the clinical availability and utility of CRISPR therapeutics. In this review, we examine what is currently known about the immunogenicity of CRISPR therapeutics and discuss several considerations to mitigate immunogenicity for the design of safe and clinically translatable CRISPR therapeutics.

Original languageEnglish (US)
Article number1138596
JournalFrontiers in Bioengineering and Biotechnology
StatePublished - 2023


  • Cas9
  • clinical translation
  • clinical trials
  • CRISPR-Cas
  • gene therapy
  • genome editing
  • immunogenicity

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Histology
  • Biomedical Engineering


Dive into the research topics of 'Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation'. Together they form a unique fingerprint.

Cite this